For patients diagnosed with lymphoma, the journey is often characterized by cycles of hope, treatment, and recovery. However, for a significant subset of the patient population, the path is complicated by the return of disease or a failure to respond to initial therapies. To provide clarity, clinical insight, and actionable guidance for these individuals, the Lymphoma Research Foundation is hosting a critical virtual educational event: "Ask the Doctor About Lymphoma: Navigating Relapsed/Refractory Disease."
Scheduled for Wednesday, June 17, 2026, from 4:00 PM to 6:00 PM ET, this two-hour program serves as a vital bridge between complex clinical research and the daily realities faced by patients and their support networks.
The Core Challenge: Understanding Relapsed and Refractory Disease
When a patient hears that their lymphoma—or related conditions like Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)—has returned, the psychological and physical toll is immense. In clinical terms, "relapsed" disease refers to a cancer that reappears after a period of improvement or remission, while "refractory" disease describes a cancer that does not respond to treatment, or responds only briefly, from the outset.
The "Ask the Doctor" program is designed to demystify these clinical classifications. By providing a forum where patients can interact directly with medical experts, the foundation aims to empower attendees to navigate the often-bewildering landscape of second-line therapies, clinical trials, and personalized medicine.
Why This Program Matters
Medical advancements in hematology and oncology are occurring at an unprecedented pace. From CAR T-cell therapy and bispecific antibodies to novel small-molecule inhibitors, the landscape for treating relapsed/refractory lymphoma is shifting. However, for the average patient, determining which of these options is appropriate for their specific subtype of lymphoma—be it Hodgkin or Non-Hodgkin—is a daunting task. This program aims to distill these advancements into accessible, actionable information.
Event Chronology: What to Expect
The event is structured to maximize engagement and ensure that attendees leave with a better understanding of their diagnostic and treatment pathways.
- 15:45 – 16:00 ET (Pre-Program): Virtual "doors" open. Attendees are encouraged to log in early to ensure their Zoom connection is stable and their audio is functioning correctly.
- 16:00 – 16:45 ET (Comprehensive Overview): The session will open with a deep-dive lecture from a leading expert in the field. This segment will cover the current standard of care for relapsed/refractory patients, the role of prognostic markers, and the importance of biomarker testing in determining future therapeutic steps.
- 16:45 – 17:45 ET (Interactive Q&A): This is the hallmark of the "Ask the Doctor" series. Attendees will have the opportunity to submit questions in real-time. Whether inquiring about side-effect management, the logistics of participating in a clinical trial, or the emotional impact of a recurrence, this segment is designed to provide personalized perspectives.
- 17:45 – 18:00 ET (Closing and Resources): The session concludes with a summary of available resources, including how to access future support groups, clinical trial matching services, and educational literature provided by the Foundation.
Supporting Data and Clinical Landscape
To understand the necessity of this program, one must look at the current oncology landscape. Recent data from the National Cancer Institute indicates that while survival rates for various lymphomas have improved significantly over the last two decades, the management of relapsed cases remains a primary focus of clinical research.
The Shift Toward Precision Medicine
The modern approach to relapsed/refractory lymphoma is increasingly centered on "Precision Medicine." This involves genetic testing of the tumor to identify specific mutations that might be susceptible to targeted therapies. Attendees will learn:
- The importance of biopsy: Why re-biopsying a lesion after a relapse is crucial for confirming the diagnosis and checking for histologic transformation.
- Clinical Trial Enrollment: Understanding that clinical trials are not a "last resort" but a viable, often superior, treatment pathway for relapsed patients.
- Multidisciplinary Care: The necessity of having a team that includes hematologist-oncologists, radiation oncologists, and, when appropriate, transplant specialists.
Expert Insight: Featuring Dr. Elizabeth Brem
The program will feature Dr. Elizabeth Brem, a distinguished expert in the field of lymphoma. Dr. Brem brings extensive experience in clinical research and patient care, making her uniquely qualified to address the nuances of refractory disease. Her presentation will focus on the "next steps" patients should consider, emphasizing the importance of informed decision-making.
By engaging with a specialist of Dr. Brem’s caliber, patients and care partners are afforded an opportunity to cut through the noise of internet-based medical information and receive evidence-based insights that are specific to the realities of modern hematology.
Implications for Patients and Care Partners
The implications of this program extend far beyond the two hours spent on Zoom. For many, the diagnosis of a relapse brings a sense of helplessness. This program serves as an intervention against that feeling.
Empowerment Through Knowledge
When patients understand the why behind their treatment changes, they are better equipped to advocate for themselves. Whether it is asking their local oncologist for a referral to a high-volume academic center or inquiring about the availability of specific chimeric antigen receptor (CAR) T-cell therapies, the information gained during this forum can fundamentally change the trajectory of a patient’s care.
The Role of Care Partners
Lymphoma does not affect the patient in isolation. Care partners—spouses, children, friends, and support staff—carry a heavy burden. The "Ask the Doctor" program recognizes this by inviting care partners to attend. By understanding the clinical goals and the potential side effects of new therapies, care partners can provide more effective support and help manage the practical aspects of a treatment plan.
Registration and Logistics
The program is held virtually via Zoom, ensuring that patients across the country can participate regardless of their geographic location or physical mobility.
How to Register
- Online: Visit the official event page to complete the registration form.
- Phone/Email: For those who prefer direct assistance, the Foundation’s Helpline is available at 800-500-9976 or via email.
- Access: Once registered, attendees will receive an email containing the Zoom link and call-in instructions.
A Note for Industry Professionals
The Foundation maintains strict boundaries between educational programming and commercial interests. While this program is open to patients, survivors, and their support networks, pharmaceutical industry professionals interested in attendance or sponsorship opportunities are directed to reach out to the Foundation’s partnership team directly to ensure compliance with the program’s educational integrity.
Disclaimer and Final Thoughts
It is essential for all attendees to recognize that while this program is an invaluable educational resource, it does not replace the professional relationship between a patient and their primary oncologist. The information provided is for educational purposes and should serve as a springboard for further conversation with a patient’s specific healthcare team.
As we look toward the date of June 17, 2026, the focus remains clear: providing hope through education. For those facing the uncertainty of relapsed or refractory lymphoma, this program offers more than just information—it offers a community of support and the professional guidance necessary to move forward with confidence.
Register today to take an active role in your care and navigate your lymphoma journey with the latest medical insights at your fingertips.
